Search results for " Basic"

showing 10 items of 10515 documents

Podoplanin serum and urine concentration in transitional bladder cancer

2016

Background Podoplanin (PDP) is a mucin - a type of transmembrane protein expressed in numerous tissues during ontogeny and in adult animals, including the brain, heart, kidney, osteoblasts and lymphoid organs. Objective The aim of this study was to determine podoplanin concentration in the blood serum and urine of patients with bladder cancer. Quantifying podoplanin concentration and its correlation with various clinicopathological parameters may be useful for more accurate predictions and identifying high-risk patients. Methods The present study included 82 patients with bladder cancer confirmed by transurethral resection or cystectomy and 27 healthy volunteers. The Surface Plasmon Resonan…

Male0301 basic medicineCancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentUrineCystectomy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBlood serumBiomarkers TumorGeneticsmedicineHumansAgedNeoplasm StagingCarcinoma Transitional CellKidneyCreatinineMembrane GlycoproteinsBladder cancerbusiness.industryGeneral MedicineMiddle AgedSurface Plasmon Resonancemedicine.disease030104 developmental biologymedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsOncologyPodoplaninchemistryCreatinine030220 oncology & carcinogenesisFemalebusinessCancer Biomarkers
researchProduct

Infiltrating mast cell-mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotype

2019

Abstract Tumor growth and development is determined by both cancer cell–autonomous and microenvironmental mechanisms, including the contribution of infiltrating immune cells. Because the role of mast cells (MC) in this process is poorly characterized and even controversial, we investigated their part in breast cancer. Crossing C57BL/6 MMTV-PyMT mice, which spontaneously develop mammary carcinomas, with MC-deficient C57BL/6-KitW-sh/W-sh (Wsh) mice, showed that MCs promote tumor growth and prevent the development of basal CK5-positive areas in favor of a luminal gene program. When cocultured with breast cancer cells in vitro, MCs hindered activation of cMET, a master regulator of the basal pr…

Male0301 basic medicineCancer ResearchReceptor ErbB-2Estrogen receptorBreast NeoplasmsMice TransgenicCell CommunicationCell Growth ProcessesMice03 medical and health sciences0302 clinical medicineBreast cancerImmune systemCell Line TumormedicineAnimalsHumansMast CellsNeoplasm Metastasisskin and connective tissue diseasesEstrogen receptor activityMice Inbred BALB Cbusiness.industryMammary Neoplasms ExperimentalCancerProto-Oncogene Proteins c-metmedicine.diseaseMast cellPhenotypeErbB ReceptorsMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureReceptors EstrogenOncology030220 oncology & carcinogenesisCancer researchFemalebusinessmast cell estrogen receptor breast cancer luminal phenotypeEstrogen receptor alpha
researchProduct

Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells.

2018

Berberine (BBR) is a common nutraceutical consumed by millions worldwide. BBR has many different effects on human health, e.g., diabetes, diarrhea, inflammation and now more recently it has been proposed to have potent anti-cancer effects. BBR has been shown to suppress the growth of cancer cells more than normal cells. BBR has been proposed to exert its growth-inhibitory effects by many different biochemical mechanisms including: suppression of cell cycle progression, induction of reactive oxygen species, induction of apoptosis and autophagy and interactions with DNA potentially leading to DNA damage, and altered gene expression. Pancreatic cancer is a leading cancer worldwide associated w…

Male0301 basic medicineCancer ResearchSettore MED/09 - Medicina InternaBerberineDNA damagePopulationSignal transduction inhibitorsApoptosisInflammation03 medical and health sciences0302 clinical medicineCell Line TumorPancreatic cancerGeneticsmedicineHumanseducationChemotherapeutic drugMolecular BiologySignal transduction inhibitorAgededucation.field_of_studybusiness.industryCell CycleAutophagyCancerPDACDNA Neoplasmmedicine.diseaseGene Expression Regulation NeoplasticPancreatic Neoplasms030104 developmental biologyApoptosis030220 oncology & carcinogenesisCancer cellCancer researchMolecular MedicineChemotherapeutic drugsmedicine.symptombusinessDNA DamageSignal Transduction
researchProduct

Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth

2018

Abstract The Wnt/β-catenin pathway regulates T-cell functions, including the repression of effector functions to the advantage of memory development via Tcf1. In a companion study, we demonstrate that, in human cancers, Wnt3a/β-catenin signaling maintains tumor-infiltrating T cells in a partially exhausted status. Here, we have investigated the effects of Wnt3a neutralization in vivo in a mouse tumor model. Abundant Wnt3a was released, mostly by stromal cells, in the tumor microenvironment. We tested whether Wnt3a neutralization in vivo could rescue the effector capacity of tumor-infiltrating T cells, by administering an antibody to Wnt3a to tumor-bearing mice. This therapy restrained tumor…

Male0301 basic medicineCancer Researchanimal structuresStromal cellT cellmedicine.medical_treatmentImmunologyAdenocarcinomaCD8-Positive T-LymphocytesDendritic CellSettore MED/0403 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmunology; Cancer Research; Wnt; Beta-catenin.Cell Line TumorWnt3A ProteinmedicineAnimalsHumansWnt Signaling PathwayColonic NeoplasmTumor microenvironmentAnimalChemistryEffectorStromal CellWnt signaling pathwayCD8-Positive T-LymphocyteDendritic CellsImmunotherapyDendritic cellCell biologyMice Inbred C57BLbody regions030104 developmental biologymedicine.anatomical_structureLymphocyte Transfusion030220 oncology & carcinogenesisColonic Neoplasmsembryonic structuresImmunotherapyStromal CellsCD8HumanCancer Immunology Research
researchProduct

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled ana…

2021

Few studies have explored the association between baseline characteristics and the occurrence of early toxicities in patients treated with first-line chemotherapy for metastatic colorectal cancer (mCRC).Individual patient data of 2190 patients enrolled in 10 prospective FFCD (Fédération Francophone de Cancérologie Digestive) trials were analysed. Severe early toxicity was defined as the occurrence of grade ≥III toxicity within 3 months after initiation of chemotherapy (ET3).Patients received monotherapy based on 5-FU (n = 1068), a cytotoxic doublet (n = 395) or tritherapy with a cytotoxic doublet plus anti-VEGF agent or a cytotoxic triplet (n = 727). The patients received 5-FU (100%), Irino…

Male0301 basic medicineCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancermedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProspective StudiesNeoplasm MetastasisAgedAfliberceptChemotherapyPerformance statusbusiness.industryMiddle AgedPrognosismedicine.diseaseOxaliplatinIrinotecanTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisToxicityFemaleColorectal Neoplasmsbusinessmedicine.drugEuropean Journal of Cancer
researchProduct

Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA

2018

Background: Scant real-world data exist on the clinical outcomes associated with the use of bevacizumab-containing chemotherapy (B+CT) in patients with metastatic colorectal cancer (mCRC). The primary objective of the GRETA cohort study was to compare the overall survival (OS) of patients with mCRC treated with first-line B+CT versus chemotherapy (CT) alone, in an Italian clinical practice setting. Materials and Methods: Incident patients with mCRC were identified during the period 2010–2012 from five population-based cancer registries in Italy. Cases were linked to regional health care utilization databases to obtain the entire spectrum of health services provided to each patient. Patients…

Male0301 basic medicineCancer Researchmedicine.medical_specialtyBevacizumabPropensity scoreColorectal cancerHealth Outcomes and Economics of Cancer CarePopulationSettore MED/42 - Igiene Generale E ApplicataCohort StudiesColorectal neoplasm03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineSurvival analysiInternal medicineObservational studymedicineHumansNeoplasm MetastasiseducationAgededucation.field_of_studybusiness.industryHazard ratioCancerMiddle Agedmedicine.diseaseBevacizumab030104 developmental biologyOncology030220 oncology & carcinogenesisPropensity score matchingCohortFemaleColorectal Neoplasmsbusinessmedicine.drugCohort study
researchProduct

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treat…

2020

Background Cancer patients are thought to have an increased risk of developing severe Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, predictive factors for COVID-19 severity and mortality in cancer patients were investigated. Patients and Methods In this large nationwide retro-prospective cohort study, we collected data on patients with solid tumours and COVID-19 diagnosed between March 1 and June 11, 2020. The primary endpoint was all-cause mortality and COVID-19 severity, defined as admission to an intensive care unit (ICU) and/or mechanical ventilation and/or death, was one of the secondary endpoints. Results From April 4 to June 11, 2020, 1289…

Male0301 basic medicineCancer Researchmedicine.medical_treatmentDiseaselaw.inventionCohort Studies0302 clinical medicineMechanical ventilationRisk FactorslawNeoplasmsMedicineProspective StudiesProspective cohort studyOriginal ResearchCancerIntensive care unit3. Good healthDeathOncology030220 oncology & carcinogenesisFemaleFranceImmunotherapyCohort studymedicine.medical_specialtychemotherapy. radiotherapyAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInternal medicineHumansChemotherapyIntensive care unitMortalityPandemicsAgedRetrospective StudiesChemotherapyRadiotherapySARS-CoV-2business.industryCancerCOVID-19Retrospective cohort studyOdds ratiomedicine.diseaseAged; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; COVID-19/mortality; Cohort Studies; Female; France/epidemiology; Humans; Male; Neoplasms/mortality; Neoplasms/therapy; Neoplasms/virology; Pandemics; Prospective Studies; Retrospective Studies; Risk Factors; SARS-CoV-2/isolation & purification; COVID-19; Cancer; Chemotherapy; Death; Immunotherapy; Intensive care unit; Mechanical ventilation; Mortality; Radiotherapy030104 developmental biologybusiness
researchProduct

Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis

2020

Abstract Background Cancer patients often suffer from psychological distress. Psycho‐oncological services (POS) have been established in some health care systems in order to address such issues. This study aims to identify patient and center characteristics that elucidate the use of POS by patients in prostate cancer centers (PCCs). Methods Center‐reported certification and patient survey data from 3094 patients in 44 certified PCCs in Germany were gathered in the observational study (Prostate Cancer Outcomes). A multilevel analysis was conducted. Results Model 1 showed that utilization of POS in PCCs is associated with patients’ age (OR = 0.98; 95%‐CI = 0.96‐0.99; P < .001), number of como…

Male0301 basic medicineCancer Researchmedicine.medical_treatmentprostate neoplasmsAndrogen deprivation therapyProstate cancer0302 clinical medicineProspective StudiesOriginal ResearchAged 80 and overProstatectomyHealth services researchpsychosocial oncologyMiddle AgedPrognosisprostate cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality Therapyhealth services researchOncology030220 oncology & carcinogenesismultilevel analysisAdultmedicine.medical_specialtyPsycho-Oncologylcsh:RC254-28203 medical and health sciencesInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingWatchful WaitingAgedProstatectomybusiness.industryPsychosocial Support SystemsProstatic NeoplasmsClinical Cancer ResearchCancerAndrogen Antagonistsmedicine.diseasePsychotherapy030104 developmental biologypsycho‐oncologyProstate neoplasmObservational studybusinessWatchful waitingFollow-Up StudiesCancer Medicine
researchProduct

Melatonin protects rats from radiotherapy-induced small intestine toxicity

2017

Radiotherapy-induced gut toxicity is among the most prevalent dose-limiting toxicities following radiotherapy. Prevention of radiation enteropathy requires protection of the small intestine. However, despite the prevalence and burden of this pathology, there are currently no effective treatments for radiotherapy-induced gut toxicity, and this pathology remains unclear. The present study aimed to investigate the changes induced in the rat small intestine after external irradiation of the tongue, and to explore the potential radio-protective effects of melatonin gel. Male Wistar rats were subjected to irradiation of their tongues with an X-Ray YXLON Y.Tu 320-D03 irradiator, receiving a dose o…

Male0301 basic medicineCancer TreatmentDrug Evaluation Preclinicallcsh:MedicineExpressionApoptosisToxicologyPathology and Laboratory Medicinemedicine.disease_causeBiochemistryOxidative Phosphorylation0302 clinical medicineIntestinal mucosaGastrointestinal tractIntestine SmallMedicine and Health SciencesRadiation-injuryIntestinal Mucosalcsh:ScienceEnergy-Producing OrganellesMelatoninCancerMultidisciplinaryNF-kappa BInflammasomeLipid-peroxidationGlutathioneMitochondriaRadiation therapyRadiation Injuries Experimentalmedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer treatmentToxicityInflammasome activationSmall IntestineExperimental pathologyAnatomyCellular Structures and OrganellesResearch Articlemedicine.drugClinical OncologyMucositismedicine.medical_specialtyRadiation TherapyRadiation-Protective AgentsBioenergeticsBiologyRadiation enteropathyMelatonin03 medical and health sciencesTongueInternal medicineSepsisNLR Family Pyrin Domain-Containing 3 ProteinmedicineAnimalsRats WistarMouthToxicitylcsh:RBiology and Life SciencesCell BiologySmall intestinemedicine.diseaseHormonesSmall intestinePathobiologyGastrointestinal TractOxidative Stress030104 developmental biologyEndocrinologylcsh:QClinical MedicineDigestive SystemGelsOxidative stress
researchProduct

Variant recurrence in neurodevelopmental disorders: the use of publicly available genomic data identifies clinically relevant pathogenic missense var…

2019

Next-generation sequencing has revealed the major impact of de novo variants (DNVs) in developmental disorders (DD) such as intellectual disability, autism, and epilepsy. However, a substantial fraction of these predicted pathogenic DNVs remains challenging to distinguish from background DNVs, notably the missense variants acting via nonhaploinsufficient mechanisms on specific amino acid residues. We hypothesized that the detection of the same missense variation in at least two unrelated individuals presenting with a similar phenotype could be a powerful approach to reveal novel pathogenic variants. We looked for variations independently present in both our database of >1200 solo exomes and…

Male0301 basic medicineCandidate geneDevelopmental DisabilitiesMutation Missense030105 genetics & heredityBiology03 medical and health sciencesNeurodevelopmental disorderIntellectual DisabilityDatabases GeneticIntellectual disabilitymedicineHumansMissense mutationExomeGenetic Predisposition to DiseaseGenetic TestingAutistic DisorderGeneGenetics (clinical)Exome sequencingGeneticsComputational BiologyHigh-Throughput Nucleotide SequencingGenomicsSequence Analysis DNAmedicine.diseasePhenotype030104 developmental biologyNeurodevelopmental DisordersAutismFemaleTranscription FactorsGenetics in Medicine
researchProduct